Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The New Economy and its Winners -- Ignore unavailable to you. Want to Upgrade?

To: Lizzie Tudor who wrote (12032)	6/13/2002 12:26:46 PM
From: Bill Harmond	Respond to of 57684

11:52 ET NPSP NPS Pharm gives positive presentation at conference (14.07 +0.01) We are hearing from a source listening to NPSP's presentation at the Goldman Sachs Healthcare conference that the co is making some positive comments: co is increasingly confident that they have solved the problem with the Preos batches (stock has suffered on Preos manufacturing problems); says they plan to bring numerous compounds to clinic under their collaboration with AZN; ALX0600 (in collaboration with AMGN) data has been very encouraging; and the co hopes to file an NDA in 2H03 for their hyperparathyroidism drug (with AMGN).